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The six-transmembrane protein Stamp2 plays an
important role in metabolically triggered inflam-
mation and insulin action. We report that Stamp2
is expressed in human and mouse macrophages,
is regulated upon differentiation or activation, acts
as an anti-inflammatory protein, and regulates foam
cell formation. Absence of Stamp2 results in
significant increases in cellular NADPH levels, and
both NADPH homeostasis and the exaggerated
inflammatory response of Stamp2/ macrophages
are rescued by exogenous wild-type but not by
a reductase-deficient Stamp2 molecule. Chemical
and genetic suppression of NADPH production in
Stamp2/ macrophages reverts the heightened
inflammatory response. Stamp2 is detected in
mouse and human atherosclerotic plaques, and its
deficiency promotes atherosclerosis in mice.
Furthermore, bone marrow transplantation experi-
ments demonstrated that Stamp2 in myeloid cells
is sufficient to protect against atherosclerosis.
Our data reveal a role of Stamp2 in controlling
intermediary metabolites to regulate inflammatory
responses in macrophages and in progression of
atherosclerosis.
INTRODUCTION
Metaflammation, the chronic, low-grade and metabolically
orchestrated immune response at key metabolic organs,
including adipose tissue, is a hallmark of obesity and contrib-
utes to related complications such as insulin resistance and
beta cell dysfunction (Eguchi et al., 2012; Hotamisligil, 2006;
Schenk et al., 2008; Shoelson et al., 2006). Importantly, meta-
bolic and inflammatory signals are tightly linked, and their coor-dinated action is important for the maintenance of metabolic
homeostasis. This is best exemplified by the fact that both
nutrients (such as glucose and lipids) and cytokines are able
to activate inflammatory and stress signaling pathways like
JNK, IKK, PKR, and others, leading to aberrant immune
response, insulin resistance, beta cell dysfunction, metabolic
dysregulation, and type 2 diabetes (Hotamisligil, 2006; Lumeng
and Saltiel, 2011; Medzhitov, 2008). There are also intimate
interactions between metabolic and immune effectors at sites
critical for metabolic homeostasis, such as macrophages and
adipocytes in adipose tissue, Kuppfer cells and hepatocytes
in liver, and many others, which are critical for metabolic regu-
lation and chronic disease (Olefsky and Glass, 2010). Since
these cells also share many of the same molecules and
networks that respond to nutrient- or pathogen-related signals,
the proper function of this complex and highly integrated
system requires proper control to maintain homeostasis, and
these are not well understood.
The impact of nutrients on inflammatory pathways demands
the existence of counterregulatory mechanisms to prevent overt
inflammation or to mitigate stress upon physiological fluctua-
tions in nutrient availability and transient surges at critical cells
or organs. Recently, the six-transmembrane protein of prostate
(Stamp)-2 was discovered as a potential molecule involved
in such a role in adipose tissue (Wellen et al., 2007). Stamp2,
also known as TNF-induced adipose-related protein (TIARP) or
six-transmembrane epithelial antigen of prostate 4 (STEAP4),
belongs to a family of six-transmembrane proteins, termed either
the STAMP or STEAP family. Three of the four family members,
including Stamp2, were recently characterized as reductases
(Ohgami et al., 2006). Stamp2 is significantly regulated by fasting
and feeding in visceral adipose tissue and was demonstrated
to be required for normal metabolic homeostasis. Despite higher
baseline levels, the nutritional regulation of Stamp2 in visceral
adipose tissue is defective in obese models and total body
Stamp2 deficiency leads to severe inflammation of visceral white
adipose tissue and recapitulates features of the metabolic
syndrome (Wellen et al., 2007). These findings indicate apotential
role for Stamp2 in the development of metabolic syndromeCell Metabolism 16, 81–89, July 3, 2012 ª2012 Elsevier Inc. 81
Figure 1. Expression and Regulation of
Stamp2 in Macrophages
(A–C) Human THP-1 monocytes were treated with
100 ng/ml PMA or vehicle for indicated time points
followed by assessment of Stamp2 mRNA (A) or
protein expression (B and C) (n = 4-5).
(D–F) Primary peritoneal macrophages were
treated with LPS (100 ng/ml), Zymosan (50 mg/ml),
or Poly I:C (50 mg/ml) followed by evaluation of
Stamp2 mRNA (D) or protein expression (E and F)
(n = 4–5).
(G) IL-6 mRNA expression was assessed in
primary WT and Stamp2/ macrophages at
baseline and after treatment with LPS (10 ng/ml for
24 hr) (n = 6–8).
(H) IL-6 secretion into the culture medium by cells
treated as in (G) was measured and normalized to
cellular protein content (n = 9–12). Data are pre-
sented as means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001 in Student’s t test.
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responses.
Stamp2 expression was recently shown to be increased in the
joints and spleen of a mouse model of inflammatory arthritis (In-
oue et al., 2009). In this model as well as in adipose tissue of
human obese subjects, where basal expression level is regu-
lated similar to mousemodels, Stamp2 expression does, at least
in part, colocalize or correlate with the macrophage marker
CD68 (Arner et al., 2008). Stamp2 expression has also been de-
tected in circulating monocytes, and expression levels were
reduced in humans with metabolic syndrome compared to
healthy controls. Furthermore, decreased Stamp2 expression
in these cells was inversely correlated with carotid plaque forma-
tion as determined by ultrasonography (Wang et al., 2010).
Hence, we postulated that Stamp2 may have a regulatory role
in macrophages and could contribute to atherosclerosis, in
which macrophage inflammatory responses play a critical role.
Here, we report that Stamp2 controls inflammatory responses
in macrophages by regulating intermediary metabolism and
that its deficiency accelerates atherosclerosis.82 Cell Metabolism 16, 81–89, July 3, 2012 ª2012 Elsevier Inc.RESULTS
Role of Stamp2 in Macrophage
Inflammatory Responses
We first examined the expression and
potential differentiation-dependent reg-
ulation of Stamp2 in macrophages. Under
basal conditions, human monocytic
THP-1 cells expressed very low amounts
of Stamp2 protein. However, Stamp2
expression was time-dependently and
robustly upregulated upon differentiation
of cells with PMA, both at the mRNA
and protein level (Figures 1A–1C). We
next analyzed whether Stamp2 exp-
ression in macrophages was subject to
regulation by inflammatory stimuli. We
treated immortalized bone marrow-derived mouse macrophages with the toll-like receptor (TLR)
agonists Lipopolysaccharide (LPS), Zymosan, and Polyinosinic:
polycytidylic acid (Poly I:C). All of these agents induced a strong
increase of Stamp2 expression, both at the mRNA and protein
levels (Figures S1A–S1C). In parallel experiments with primary
peritoneal macrophages from wild-type (WT) mice, treatment
with TLR agonists again induced a substantial increase of
Stamp2 expression both in mRNA and protein levels (Figures
1D–1F). These data show that Stamp2 is expressed in both
mouse and human macrophages and exhibits strong positive
regulation during differentiation and by inflammatory stimuli.
We then examined whether Stamp2 has a direct role in
modulating the inflammatory response and analyzed expres-
sion of inflammatory cytokines in primary macrophages from
Stamp2/ and WT mice. In these experiments, we observed
significantly greater induction of IL-6, MCP-1, IL-1b, and TNF-a
mRNA expression in Stamp2/ macrophages compared to
WT cells after LPS treatment (Figures 1G and S1D–S1F). In line
with these observations, LPS-induced secretion of IL-6,
MCP-1, IL-1b, and TNF-a into the culture medium was also
Figure 2. Regulation of iNOS Expression
and NO Production by Stamp2
(A–C) Expression of iNOS was detected at the
mRNA (A) and protein level (B and C) in primaryWT
and Stamp2/ macrophages treated with LPS
(10 ng/ml for 24 hr) (n = 6–10).
(D) NO production was measured in culture
medium from cells treated with LPS (10 ng/ml) for
24 hr normalized for cellular protein content (n =
11).
(E) Primary peritoneal macrophages were treated
with the iNOS inhibitor W1400 (10 mM) and 2 hr
later stimulated with LPS (100 ng/ml for 4 hr) fol-
lowed by assessment of IL-6 mRNA expression
(n = 4).
(F) Primary Stamp2/ macrophages were elec-
troporated with Stamp2-expressing vector, cata-
lytic domain-deficient Stamp2 expressing-vector
(Stamp2DN), or control plasmids (mutant depicted
in the top panel).
(G) IL-6 mRNA expression is shown after LPS
(100 ng/ml for 4 hr) treatment following electro-
poration with vectors mentioned in (F) (n = 3). Data
are presented as means ± SEM, *p < 0.05 in
Student’s t test.
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to WT cells (Figures 1H and S1G–S1I).
Earlier studies have shown impaired insulin action and glucose
transport in Stamp2 knockdown adipocytes and in Stamp2/
adipose tissue (Wellen et al., 2007). Since insulin resistance in
macrophages has been implicated in enhanced stress
responses in these cells (Han et al., 2006), we examined
insulin-induced Akt phosphorylation. However, we detected no
differences in the insulin responsiveness of Stamp2/ and WT
macrophages (Figures S1J and S1K). Taken together, these
data indicate that macrophages lacking Stamp2 expression
are prone to an enhanced inflammatory response, but unlike
adipocytes, they do not exhibit decreased insulin sensitivity.
Mechanisms Underlying the Overt Inflammatory
Phenotype of Stamp2 Deficiency
Expression of inducible nitric oxide synthase (iNOS) increases
during macrophage activation. As shown in Figures 2A–2C,
iNOS mRNA and protein expression were enhanced to a signif-
icantly greater extent in Stamp2/ macrophages compared
to WT cells upon treatment with LPS. In this setting, LPS-
induced cellular release of NO into the culture medium wasCell Metabolism 16,significantly higher in Stamp2-deficient
macrophages (Figure 2D). This led us to
consider NO production by iNOS as
a mechanism by which Stamp2 regulates
inflammatory responses. We treated
Stamp2-deficient macrophages with
a highly iNOS-specific inhibitor, W1400
(Fedorov et al., 2003). Interestingly, inhi-
bition of iNOS had no effect on LPS-
induced expression of IL-6 in Stamp2/
and WT macrophages (Figure 2E), illus-
trating that the changes in iNOS expres-sion cannot account for the enhanced inflammatory response in
Stamp2/ macrophages.
This led us to examine causality of defective Stamp2 function
for the proinflammatory phenotype seen in macrophages by
reintroducing full-length Stamp2 back into Stamp2/ macro-
phages. As Stamp2 possesses an oxidoreductase domain that
may serve an enzymatic function, we also added back an
oxidoreductase-deficient mutant form of Stamp2 (Stamp2DN).
As shown in Figure 2F, this approach led to comparable expres-
sion of either Stamp2 or Stamp2DN in Stamp2/macrophages.
Furthermore, re-expression of wild-type Stamp2 dampened the
LPS-induced proinflammatory gene expression in Stamp2/
cells (Figure 2G), demonstrating the causal role of Stamp2 for
the observed phenotype. In contrast, oxidoreductase-deficient
Stamp2DN did not exhibit a similar ability to suppress inflamma-
tion (Figure 2G). Based on these findings, we concluded that the
oxidoreductase domain of Stamp2, and the activity it possesses,
is critical for Stamp2’s ability to dampen inflammation.
Next, we investigated the potential role of the oxidoreductase
activity of Stamp2 in the control of the inflammatory response.
In fact, the oxidoreductase domain of Stamp2 features a
Rossman Fold homology sequence that is largely conserved81–89, July 3, 2012 ª2012 Elsevier Inc. 83
Figure 3. NADPH-Dependent Regulation of
Inflammatory Responses by Stamp2 in
Macrophages
(A) NADPH levels were measured in Stamp2/
and WT primary peritoneal macrophages.
Homology of STAMP familymemberswith NADPH
binding Rossman Fold domain is depicted in the
top panel.
(B–D) G6PDx was inhibited in primary peritoneal
macrophages by 50 mM DHEA followed by LPS
treatment (100 ng/ml) and assessment of IL-6
mRNA expression (B). RNA interference directed
against G6PDx gene resulted in >70%knockdown
of the gene (C). IL-6 mRNA expression was as-
sessed 24 hr after siRNA-induced knockdown of
G6PDx and after LPS treatment (D) (n = 3).
(E) Primary peritoneal macrophages from
Stamp2/mice were electroporated as in Figures
2E and 2F, followed by analysis of NADPH levels
(n = 4–5).
(F and G) Primary peritoneal macrophages were
treated with LPS or vehicle followed by western
blot analyses of the expression of phosphorylated
and total proteins.
(H and I) Cell lysates as in (F) were used to prepare
nuclear and cytosolic fractions followed by
western blot analyses of NMRAL1 expression and
Lamin A/HSP90 expression as loading controls
(n = 4). Data are presented as means ± SEM, *p <
0.05, in Student’s t test.
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top insert). This raises the possibility that Stamp2 utilizes NADPH
for reductive catalysis and may be implicated in the regulation of
cellular NADPH homeostasis. Therefore, we measured NADPH
levels in Stamp2/ and WT primary peritoneal macrophages.
As shown in Figure 3A, Stamp2/ macrophages had signifi-
cantly higher levels of cellular NADPH compared to WT controls.
Given the role of NADPH in inflammatory processes, we then
postulated that this excess NADPH availability could be fueling
the overt inflammatory phenotype observed in Stamp2 defi-
ciency. To test this hypothesis, we genetically and pharmacolog-
ically inhibited the primary NADPH-producing enzyme glucose
6-phosphate dehydrogenase (G6PDx) in Stamp2/ cells.
Chemical inhibition with dehydroepiandrosterone (DHEA)
decreased NADPH levels (Figure S2A), was not cyto- or proteo-
toxic (Figures S2B and S2C), and essentially completely blocked
LPS-induced IL-6 expression in Stamp2/ macrophages (Fig-
ure 3B). To complement the chemical approach, we also tar-
geted G6PDx genetically by RNA interference. This approach
resulted in reduced G6PDx both at the mRNA and protein levels
(Figures 3, S2D, and S2E) and also significantly reduced LPS-84 Cell Metabolism 16, 81–89, July 3, 2012 ª2012 Elsevier Inc.induced IL-6 expression in Stamp2/
macrophages (Figure 3D). To assess
a direct role for Stamp2 in this regulatory
mechanism, we also tested whether we
could rescue the elevated NADPH levels
in Stamp2/ macrophages by reconsti-
tuting Stamp2 back into these cells. As
shown in Figure 3E, re-expression of WT
Stamp2 in Stamp2/ macrophages
caused a significant reduction in NADPH levels, which did not
occur when oxidoreductase-deficient Stamp2DN was intro-
duced. These data demonstrate that Stamp2 regulates NADPH
levels in macrophages, and this regulatory mechanism may be
critical for the control of inflammatory responses.
Next, we examined whether and which inflammatory signaling
pathways were altered in Stamp2/ macrophages and evalu-
ated phosphorylation of the MAP kinases ERK, JNK, and p38.
We found increased LPS-induced phosphorylation of p38 in
Stamp2/ cells compared to WT, whereas phosphorylation of
ERK and JNK was not altered (Figures 3F, 3G, S2F, and S2G).
As p38 activation is frequently associated with increased
signaling via NF-kB in immune cells, we also determined phos-
phorylation of p65. As shown in Figures 3F and 3G, LPS induced
phosphorylation of p65 to a significantly greater extent in
Stamp2/ cells compared to WT, potentially explaining the
proinflammatory phenotype. In contrast, there were no differ-
ences in TLR4 expression. It has been reported that when cellular
NADPH levels are low, the NADPH sensor protein NMRAL1
(NmrA-like family domain-containing protein 1) translocates to
the nucleus and targets p65 for degradation and furthermore
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containing protein 1) to inhibit NF-kB (Lian and Zheng, 2009;
Zheng et al., 2007). As this protein may link increased NADPH
levels to the proinflammatory phenotype, we determined regula-
tion of NMRAL1 in cytosolic and nuclear fractions in Stamp2/
cells. As shown in Figures 3H and 3I, nuclear translocation of
NMRAL1 was significantly decreased in LPS-treated Stamp2/
cells compared to WT controls. These results indicate that
Stamp2’s anti-inflammatory properties are dependent upon
regulation of NADPH metabolism by its oxidoreductase activity,
which engages inflammatory pathways. Our data also identify
at least one potential mechanism of controlling inflammatory
signaling through the NADPH sensor protein NMRAL1.
Role of Stamp2 for Macrophage Foam cell Formation
Loading of macrophages with modified lipids may promote foam
cell formation and also influence the inflammatory responses.
Hence, we assessed expression of IL-6 and TNF-a, as well as
NO production, in cells after exposure to oxLDL (Figures S2H–
S2J), and in this setting Stamp2/macrophages also exhibited
higher levels of thesemediators compared toWT cells. Using thi-
oglycollate-elicited primary macrophages we also detected
a significant increase of foam cell formation due to Stamp2-
deficiency (Figures S3A and S3B). We verified these results by
loading cells with DiI-labeled oxLDL particles, followed by quan-
tification of fluorescence intensity of the lysates normalized for
protein concentration (Devaraj et al., 2001) (Figure S3C). We
also examined the in vivo relevance of these observations in an
established macrophage transfer model (Li et al., 2004) where
thioglycollate-elicited primary macrophages were injected into
the peritoneal cavity of ApoE/ mice kept on Western diet for
6 weeks prior to the experiment. Three days later, macrophages
were recovered and stained with oil red O. In this setting, foam
cell formation of Stamp2/macrophages was higher compared
to WT cells (Figures S3D and S3E), confirming the in vivo rele-
vance of our findings. As macrophage inflammation is associ-
ated with disturbed cholesterol clearance (Chen et al., 2007;
Khovidhunkit et al., 2003), we assessed macrophage efflux of
radiolabeled cholesterol. As shown in Figure S3F, Stamp2/
macrophages showed decreased cholesterol efflux and, consis-
tent with this phenotype, exhibited a significant decrease in the
expression of the ABC transporters ABCA1 (Figures S3G–S3I)
and ABCG1 (Figures S4J–S4L). In contrast, scavenger receptor
CD36 and SR-A expression was similar between genotypes
(data not shown). These findings show that foam cell formation
of Stamp2/ macrophages was enhanced, most likely due to
impaired cholesterol efflux secondary to decreased expression
of ABC transporters. Together with the enhanced inflammatory
properties of Stamp2/macrophages, these data point toward
a potential role of Stamp2 during atherogenesis.
Deficiency of Stamp2 Promotes Early Atherosclerosis
in ApoE–/– Mice
IfmacrophageStamp2plays a role in atherosclerosis, expression
of the protein within the vascular lesion may be anticipated.
Indeed, Stamp2 was expressed in both human (Figure 4A) and
mouse (Figure 4B) atherosclerotic plaques, and expression was
colocalized with expression of macrophage markers, supporting
a role in lesional macrophages. To analyze the role of Stamp2 inearly atherosclerotic lesion formation, we crossed Stamp2/
mice with the ApoE/ model. At 6 weeks of age, littermate
mice (n = 12 Stamp2/ApoE/ and n = 10 Stamp2+/+ApoE/
mice, respectively) were challenged with Western diet for an
additional 6 weeks. On atherogenic diet, there were no statisti-
cally significant changes of glucose clearance rates, total serum
cholesterol and triglyceride levels, lipid profiles, body weight or
blood glucose levels between groups (Figures S4A–S4C). Hence,
this model serves well to analyze the impact of macrophage
contributions independent of systemic metabolic alterations.
En face analysis demonstrated a 77% increase of atherosclerotic
lesion area in the aortas of Stamp2/ApoE/ mice compared
toStamp2+/+ApoE/controls (Figures 4C–4E). Similarly, athero-
sclerotic lesions in the proximal aortas were larger in
Stamp2/ApoE/ mice (Figures 4D and 4F). In line with our
observations in cultured macrophages, lesional inflammation,
as assessed by staining for TNF-a and IL-6, was higher in
sections from Stamp2/ApoE/ mice (Figures S4D and S4E),
whereas assessment of macrophage cell count/lesion area (not
shown), smooth muscle cell staining, and van Giesson staining
revealed no significant differences (Figure S4F). We also
measured inflammatory cytokine levels in the serum of both
groups and were able to detect TNF-a and CXCL1. While there
was no difference in CXCL1 levels between groups, there was
a small but statistically significant increase in serum TNF-a levels
of Stamp2/ApoE/mice (Figure S4G). Since the changes are
rather minor, our observations support a role for Stamp2 in local,
rather than systemic, inflammatory changes in this setting. Taken
together, these data support a role for macrophage Stamp2
during atherogenesis.
However, in the whole organism, other cells and tissues may
have also contributed to the phenotype. To address this, we per-
formed bone marrow transplantation experiments to assess
whether Stamp2 deficiency in bone marrow-derived cells is
sufficient to induce early atherosclerosis. We transplanted
bone marrow collected from Stamp2/ApoE/ mice or from
ApoE/ littermates to lethally irradiated 6-week-old ApoE/
mice (n = 11 and n = 12, respectively). After 4 weeks on chow
diet post engraftment, recipient mice were challenged with
Western diet, and reconstitution with donor bone marrow was
verified by the representation of donor alleles (Figure 4G). There
were no significant differences in body weight, blood glucose
levels, total serum cholesterol or triglycerides, and lipoprotein
distribution between groups (Figures S4H and S4I). In the
en face preparations, the extent of total atherosclerotic lesion
area was significantly higher in the mice that received
Stamp2/ApoE/ bone marrow compared to mice that were
reconstituted with ApoE/ cells (Figures 4H and 4J). Further-
more, lesion area in this group was also significantly higher in
the histological analysis of proximal aortic sections, as
confirmed by staining with oil red O and MOMA-2 (Figures 4I
and 4K). These data indicate an important role of Stamp2 during
the development of atherosclerosis through its function in bone
marrow-derived cells.
DISCUSSION
In this study, we demonstrate that Stamp2 deficiency results in
an aggravated inflammatory response and increased foam cellCell Metabolism 16, 81–89, July 3, 2012 ª2012 Elsevier Inc. 85
Figure 4. Regulation of Atherosclerotic Lesion Formation in Total Body or Bone Marrow Stamp2 Deficiency
(A and B) H&E stainings along with nonimmune controls for CD68 and Stamp2 of human atherosclerotic plaques are shown (A). Below, Stamp2 staining of tissues
with known high expression of Stamp2 (adipose tissue, prostate tissue, prostate cancer tissue) are presented to further support specificity of the antibody.
RepresentativeMOMA-2 and Stamp2 immunohistochemistry stainings of murine atherosclerotic plaques from ApoE/ (top panel) and Stamp2/ApoE/mice
(as staining controls, bottom panel) (B).
(C–K) Representative Sudan IV-stained pinned en face aortic preparations (C), aortic root sections (D) staining with oil red O, and staining with MOMA-2 were
performed on ApoE/ and Stamp2/ApoE/mice after 6 weeks of Western diet (C). Quantification of atherosclerotic plaque area in en face preparations (E)
and plaque area in the aortic root sections (F) (n = 8–12). Genotyping results of blood from ApoE//ApoE/ and STAMP2/ApoE//ApoE/ mice
together with a tail DNA sample from a Stamp2+/ mouse as control (‘‘Het Control’’). The upper band depicts the Stamp2/ allele, whereas the lower band
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in vivo. The ability of Stamp2 to regulate inflammatory responses
in macrophages is dependent on its NADPH oxidoreductase
activity, and chemical or genetic inhibition of primary NADPH-
producing enzyme G6PDx can rescue the phenotype caused
by Stamp2 deficiency. These findings place Stamp2 in a vital
position for cellular NADPH catalysis, which is critical for control
of immune responses and may have important implications for
human disease. In fact, it has been reported that lower cellular
NADPH levels due to mutations in the human G6PDx gene
can dampen inflammatory responses in mononuclear cells
isolated from these subjects (Sanna et al., 2007), and humans
and mice with G6PDx deficiency appear to be protected against
atherosclerosis (Cocco et al., 1998; Matsui et al., 2006). We
detected Stamp2 expression in macrophages of both mouse
and human atherosclerotic plaques. Interestingly, decreased
Stamp2 expression is evident in circulating monocytes of hu-
mans with cardiometabolic syndrome, and expression levels
were inversely correlated with carotid atherosclerosis (Wang
et al., 2010). Hence, as a critical regulator of NADPHmetabolism,
inflammation, and atherosclerosis, Stamp2 may also play a
critical role in human cardiovascular disease in general and
promote disease particularly in the context of insulin resistance
and diabetes.
Stamp2 serves critical functions at the interface of metabolic
and inflammatory pathways through its actions in target cells
critical for metabolic and immune regulation. However, there
are differences in the function of Stamp2 in adipocytes and
macrophages. Notably, ablation of Stamp2 in cultured or primary
adipocytes leads to decreased insulin action and glucose trans-
port (Wellen et al., 2007). However, in the experimental model
used in the current study, this was not the case in macrophages.
In an atherogenic background, systemic glucose tolerance was
also not impaired in Stamp2-ApoE double-deficient mice.
Although it is possible that ApoE deficiency may have at least
partially masked potential Stamp2-related effects, these results
indicate a more direct role of Stamp2 in the control of macro-
phage inflammatory responses in a dyslipidemic environment.
This is consistent with earlier observations in another model,
where the impact of atherosclerosis has also been independent
of the effects of aP2 on systemic insulin action, which acts on
both adipocytes and macrophages (Furuhashi et al., 2007; Ma-
kowski et al., 2001). It will be interesting to explore the potential
cell autonomous effects of Stamp2 on othermetabolically critical
targets, such as hepatocytes or the central nervous system, in
the future.
An important role of Stamp2’s oxidoreductase domain was
evident for regulation of cellular NADPH levels and inflammatory
output of macrophages. These metabolic and immune functions
may also have relevance beyond atherosclerosis and influence
other disease states such as tumorigenesis. For example,
Stamp2 expression is regulated by androgens, and Stamp2 is
overexpressed in androgen receptor-positive prostate cancer
cell lines where it contributes to increased growth and colonyrepresents the WT allele (G). Representative Sudan IV-stained pinned out en fac
ApoE/mice after 8 weeks of Western diet (H), and representative aortic root sec
of atherosclerotic plaque area in en face preparations (J) and plaque area in the ao
**p < 0.01 in Mann–Whitney test.formation (Korkmaz et al., 2005). These regulatory patterns may
also be the result of Stamp2’s role in altered cellular metabolism
in tumor cells, where proliferating cells may need an increased
expression of Stamp2 to meet the increased demand for nutri-
ents. Inflammatory changes are also commonly associated
with cancers and influence the progression and outcomes.
Whether tumor formation and/or tumor inflammation are also
controlled by Stamp2 and whether this molecule contributes to
increased tumor incidence seen in obesity remain interesting
future areas of investigation. Nonetheless, the function of
Stamp2 as a regulatory protein of NADPH homeostasis and
inflammatory responses opens up possibilities of its involvement
in several pathological settings and indicate that Stamp2 may
represent a suitable target for pharmacological intervention
targeting cancer, metabolic, or cardiovascular diseases.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal care and experimental procedures were performed with approval
from animal care committees of Harvard University. Generation of Stamp2/
and wild-type mice and backcrossing to the C57BL/6 background were
performed as described previously (Wellen et al., 2007). Mice homozygous
for the inactivation of Stamp2 were intercrossed with ApoE/ mice also in
the C57BL/6 background (Jackson Laboratories) to generate mice heterozy-
gous at both loci. These Stamp2/+ApoE/+ mice were then intercrossed to
produce Stamp2/ApoE/ mice along with Stamp2+/+ApoE/ littermate
controls. Male mice were kept on a 12 hr light/dark cycle and were fed
a high-cholesterol atherogenic Western diet (D12079B: 21% fat, 0.21%
cholesterol; Research Diets) ad libitum, beginning at 6 weeks of age. Before
and after treatment, blood samples were collected from animals after 6 hr of
food withdrawal, and the glucose tolerance test was performed by intraperito-
neal glucose injection (1.5 g/kg) on conscious mice after overnight (15 hr)
food withdrawal after 5 weeks of Western diet (7 weeks in bone marrow-
transplanted mice).
Bone Marrow Transplantation
Six-week-old recipient mice were lethally irradiated with two 5 Gy doses (total
10 Gy) from a cesium source at a 4 hr interval in order to minimize radiation
toxicity. Bone marrow was collected by flushing the femurs and tibiae from
sex-matched donor mice (6–8 weeks of age) with phosphate-buffered saline
(PBS). Each recipient mouse was injected with 4 3 106 bone marrow cells in
0.2 ml PBS into the retro-orbital venous plexus. During 1 week before and
4 weeks following bone marrow transplantation (BMT), 100 mg/l neomycin
and 10mg/l polymyxin B sulfate were added to the drinking water as described
(Vallerie et al., 2008).
Assessment of Atherosclerosis and Immunohistochemistry
Perfusion fixation, preparation of aortas and quantification of atherosclerotic
lesions were performed as described (Furuhashi et al., 2007). En face pinned
aortas were stained with Sudan IV. The heart with the proximal aorta was
embedded in OCT (Sakura Finetek) and snap frozen in 2-methylbutane.
Lesions in the proximal aorta from serial 8 mm thick cryosections were stained
with oil red O and counterstained with hematoxylin. Images of the aortas and
immunohistochemistry slides were captured with a digital color camera (DP70;
Olympus) mounted on a microscope. All quantitative analysis of images were
performed using ImageJ software, and immunohistochemistry was performed
as described with the indicated antibodies (Erbay et al., 2009; Furuhashi et al.,
2007). Human aortic lesions were collected from 4 male patients and 1 femalee preparations of aortas from ApoE//ApoE/ and Stamp2/ApoE//
tions (I) stained with oil red O or stained with MOMA-2 antibody. Quantification
rtic root sections (K) (n = 8–12). Data are presented as means ± SEM, *p < 0.05,
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Stamp2 Controls Inflammation through Regulating NADPHpatient, ages ranging from 57–72, fixed in 10% formalin and paraffin
embedded until further processing. At the time of immunostaining, serial
sections were deparaffinized and stained using Stamp2 or CD68 antibody,
following a citrate buffer epitope retrieval step, and visualized with DAB. Van
Giesson and dehydroethidium staining (Zanetti et al., 2005) and biochemical
assays were performed as described (Furuhashi et al., 2007).
Examination of Macrophage Cytokine and Nitric Oxide Production
Supernatants from primary macrophages treated with LPS (Sigma) as
indicated were evaluated for the production of IL-6, MCP-1, and TNF-a by
ELISA (R&D), and IL-1b by electrochemiluminescence (MesoScale Discovery).
The iNOS inhibitor W1400 (Cayman Chemical) was used at a concentration of
10 mmol/l. Supernatants of macrophages treated as described above were
evaluated for nitric oxide production utilizing the Griess reaction with a
commercial system (Invitrogen). Cytokine and nitric oxide levels were normal-
ized to cellular protein content.
NADPH Measurements
The protocol used was adapted from a previous publication (Zhang et al.,
2000). Briefly, cells were lysed, and pyridine nucleotides were liberated from
cells with two freeze-thaw cycles followed by sonication. After pelleting
and removal of cell debris by centrifugation, absorbance was measured using
a NanoDrop 2000 (ThermoScientific) at 340 nm to measure NADPH+NADH. All
of the NADPH was converted to NADP+ using glutathione in the presence of
oxidized GSSH, and absorbance was measured at 340 nm to determine total
NADH. NADPHwas calculated by subtracting NADH fromNADPH+NADH, and
levels were normalized to total protein content.
Statistical Analysis
Experimental results are shown asmeans ± SEM.Mean values for biochemical
data from each group were compared by Student’s t test. Data on vascular
lesions, which were not normally distributed, were analyzed with a nonpara-
metric Mann–Whitney test. Comparisons between time points were analyzed
using repeated-measures analysis of variance, ANOVA. All statistical tests with
p < 0.05 were considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
cmet.2012.05.009.
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